Ex Vivo and In Vivo Characterization of Interpolymeric Blend/Nanoenabled Gastroretentive Levodopa Delivery Systems

Table 7

Mean urine concentration after oral administration of Madopar HBS capsules, PXLNET, and IPB matrices.

Time (h)	Mean urine concentration (ng/mL)
	Madopar HBS			PXLNET			IPB
	M-D	D-M	L-D	M-D	D-M	L-D	M-D	D-M	L-D
2.00	604.6	5888	196.8	1532.7	4449	784.8	459.4	111.2	425.5
4.00	853.3	21938	755.1	—	—	—	1221.8	4571.1	1328

M-D, methyldopa; D-M, dopamine; and L-D, levodopa.